With two products in Phase III development running up R&D expenses, Keryx Biopharmaceuticals Inc. is looking to raise $33 million in a registered offering of 7 million shares at $4.70 per share. Read More
SARcode Corp., of Brisbane, Calif., presented data for its lead investigational molecule, SAR 1118. In a Phase II dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production and improved visual-related function as compared to placebo. The data were part of the scientific program of the Association for Research in Vision and Ophthalmology Annual Meeting held in Fort Lauderdale, Fla. Read More
Promedior Inc., of Malvern, Pa., reported that data from preclinical studies of PRM-151 (recombinant human Pentraxin-2 [PTX-2]) were presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology in Ft. Lauderdale, Fla. In a poster, Promedior and collaborators from the Johns Hopkins University Wilmer Eye Institute highlighted the efficacy and utility of Pentraxin-2 in suppressing neovascularization in independent models of age-related macular degeneration and diabetic retinopathy. Read More
AMAG Pharmaceuticals Inc., of Lexington, Mass., reported total first quarter revenue of $13.4 million, of which $10.9 million were net product revenues from Feraheme (ferumoxytol) Injection for intravenous use to treat iron deficiency anemia in adult chronic kidney disease patients, compared to total revenue of $13.3 million for the same period in 2010. Read More
LPath Inc., of San Diego, received U.S. Patent No. 7,901,682 for methods of treatment in cancer, pathological angiogenesis and inflammation using an antibody or antibody fragment that binds sphingosine-1-phosphate. Read More
In keeping with its reputation for doing things quickly, Molecular Partners AG has secured a potential $420 million deal – a sizable $45 million of which is up front – with Allergan Inc. for its lead molecule, MP0112, within days of reporting positive Phase I/IIa data. Read More
SAN FRANCISCO – It's impossible to imagine the biotech space without monoclonal antibodies. A recent report by Deloitte Recap LLC showed that about a third of marketed mAbs in 2009 hit blockbuster status, and experts are predicting that in a few years, the top-selling drugs will be Roche AG's Avastin (bevacizumab) and Abbott's Humira (adalimumab). Read More
